Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer-A TEAM study analysis

European Journal of Cancer

Volumn 49, Issue 2, 2013, Pages 297-304

  Van De Water, Willemien ^a   Fontein, Duveken B Y ^a   Van Nes, Johanna G H ^a   Bartlett, John M S ^b,e   Hille, Elysée T M ^a   Putter, Hein ^a   Robson, Tammy ^b   Liefers, Gerrit Jan ^a   Roumen, Rudi M H ^c   Seynaeve, Caroline ^d   Dirix, Luc Y ^f   Paridaens, Robert ^g   Kranenbarg, Elma Meershoek Klein ^a   Nortier, Johan W R ^a   Van De Velde, Cornelis J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^f Algemeen Ziekenhuis St Augustinus   (Belgium)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer; Endocrine therapy; Lobular carcinoma; Oestrogen receptors

Indexed keywords

ESTROGEN RECEPTOR; EXEMESTANE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ALLRED SCORE; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; INVASIVE LOBULAR BREAST CARCINOMA; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SCORING SYSTEM;

AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84872104847     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.07.026     Document Type: Article

References (29)

1. A.R. Dixon, I.O. Ellis, C.W. Elston, and R.W. Blamey A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast Br J Cancer 63 4 1991 634 635
2. G. Arpino, V.J. Bardou, G.M. Clark, and R.M. Elledge Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome Breast Cancer Res 6 3 2004 R149 R156
3. M. Colleoni, G. Viale, and A. Goldhirsch Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting Breast 18 Suppl 3 2009 S137 S140
4. K. Jirstrom, L. Ryden, and L. Anagnostaki Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial J Clin Pathol 58 11 2005 1135 1142
5. A. Goldhirsch, J.N. Ingle, and R.D. Gelber Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 8 2009 1319 1329
6. J.M. Harvey, G.M. Clark, C.K. Osborne, and D.C. Allred Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 5 1999 1474 1481
7. International Breast Cancer Study Group (IBCSG) Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial J Natl Cancer Inst 94 14 2002 1054 1065
8. D.B. Smith, A. Howell, and J. Wagstaff Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival Eur J Cancer Clin Oncol 23 7 1987 979 982
9. E.A. Rakha, M.E. El-Sayed, and D.G. Powe Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes Eur J Cancer 44 1 2008 73 83
10. C.J. van de Velde, D. Rea, and C. Seynaeve Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial Lancet 377 9762 2011 321 331
11. A. Goldhirsch, W.C. Wood, and A.S. Coates Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 8 2011 1736 1747
12. J.M. Bartlett, C.L. Brookes, and T. Robson Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial J Clin Oncol 29 12 2011 1531 1538
13. M. Dowsett, C. Allred, and J. Knox Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial J Clin Oncol 26 7 2008 1059 1065
14. A. Qureshi, and S. Pervez Allred scoring for ER reporting and it's impact in clearly distinguishing ER negative from ER positive breast cancers J Pak Med Assoc 60 5 2010 350 353
15. J.G. van Nes, C. Seynaeve, and S. Jones Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries Br J Surg 97 5 2010 671 679
16. NHS Cancer Screening Programmes, The Royal College of Pathologists. Guidelines for pathology reporting in breast disease. NHSBSP Publication No 58; 2005.
17. A.A. Lazar, B.F. Cole, M. Bonetti, and R.D. Gelber Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot J Clin Oncol 28 29 2010 4539 4544
18. M. Bonetti, D. Zahrieh, B.F. Cole, and R.D. Gelber A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data Stat Med 28 8 2009 1255 1268
19. B.C. Pestalozzi, D. Zahrieh, and E. Mallon Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials J Clin Oncol 26 18 2008 3006 3014
20. M.J. Ellis, V.J. Suman, and J. Hoog Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031 J Clin Oncol 29 17 2011 2342 2349
21. S.R. Johnston, G. Saccani-Jotti, and I.E. Smith Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer Cancer Res 55 15 1995 3331 3338
22. L. Mauriac, A. Keshaviah, and M. Debled Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial Ann Oncol 18 5 2007 859 867
23. G. Viale, M.M. Regan, and P. Dell'Orto Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial Ann Oncol 22 10 2011 2201 2207
24. M.M. Regan, K.N. Price, A. Giobbie-Hurder, B. Thurlimann, and R.D. Gelber Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer Breast Cancer Res 13 3 2011 209
25. R. Jakesz, W. Jonat, and M. Gnant Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 9484 2005 455 462
26. A. Katz, E.D. Saad, P. Porter, and L. Pusztai Primary systemic chemotherapy of invasive lobular carcinoma of the breast Lancet Oncol 8 1 2007 55 62
27. T. Petit, M. Wilt, and M. Velten Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer Breast Cancer Res Treat 124 2 2010 387 391
28. A. Purushotham, S. Pinder, M. Cariati, M. Harries, and A. Goldhirsch Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast? J Clin Oncol 28 22 2010 3552 3554
29. S.A. Farese, and S. Aebi Infiltrating lobular carcinoma of the breast: Systemic treatment Breast Dis 30 2009 45 52